Statement: 2 patients, in cohort 1 of the primary trial was recorded as having an overactive pituitary gland.
Primary_evidence: Adverse Events 1:   Total: 52/112 (46.43%)   Febrile neutropenia * 16/112 (14.29%)   Neutropenia * 7/112 (6.25%)   Anaemia * 1/112 (0.89%)   Cardiac failure * 1/112 (0.89%)   Coronary artery disease * 1/112 (0.89%)   Left ventricular dysfunction * 1/112 (0.89%)   Pericardial effusion * 0/112 (0.00%)   Hyperthyroidism * 1/112 (0.89%)   Diarrhoea * 5/112 (4.46%)   Vomiting * 3/112 (2.68%) Adverse Events 2:   Total: 51/110 (46.36%)   Febrile neutropenia * 26/110 (23.64%)   Neutropenia * 7/110 (6.36%)   Anaemia * 1/110 (0.91%)   Cardiac failure * 0/110 (0.00%)   Coronary artery disease * 0/110 (0.00%)   Left ventricular dysfunction * 0/110 (0.00%)   Pericardial effusion * 1/110 (0.91%)   Hyperthyroidism * 0/110 (0.00%)   Diarrhoea * 0/110 (0.00%)   Vomiting * 1/110 (0.91%)